{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Treatment+C+%3A+Placebo&page=3",
    "query": {
      "intervention": "Treatment C : Placebo",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 988,
    "total_pages": 99,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Treatment+C+%3A+Placebo&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Treatment+C+%3A+Placebo&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-06T01:53:28.686Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03348904",
      "title": "Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Epacadostat",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2017-12-27",
      "completion_date": "2018-05-22",
      "has_results": true,
      "last_update_posted_date": "2019-06-13",
      "last_synced_at": "2026-10-06T01:53:28.686Z",
      "location_count": 2,
      "location_summary": "Anaheim, California • Wichita, Kansas",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Wichita",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03348904"
    },
    {
      "nct_id": "NCT07660731",
      "title": "A Study to Learn How Different Amounts of the Study Medicine Called PF-08103402 Are Tolerated and Act in the Body in Healthy Adults or Adults With Mild To-moderate Asthma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteer Study",
        "Healthy Adults",
        "Healthy Participants",
        "Asthma"
      ],
      "interventions": [
        {
          "name": "PF-08103402",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Midazolam",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 133,
      "start_date": "2026-06-17",
      "completion_date": "2027-03-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-02",
      "last_synced_at": "2026-10-06T01:53:28.686Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07660731"
    },
    {
      "nct_id": "NCT04505566",
      "title": "INflammatory MediatorS in the PathophysIology of Diabetic REtinopathy Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetic Retinopathy"
      ],
      "interventions": [
        {
          "name": "Ketorolac 0.45% ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "Placebo - Preservative-free artificial tears",
          "type": "DRUG"
        },
        {
          "name": "Aqueous PGE2 and inflammatory cytokines measurements",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Stephen J. Kim, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 164,
      "start_date": "2020-11-09",
      "completion_date": "2026-04-21",
      "has_results": false,
      "last_update_posted_date": "2026-08-21",
      "last_synced_at": "2026-10-06T01:53:28.686Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04505566"
    },
    {
      "nct_id": "NCT01240759",
      "title": "Safety and Efficacy of S-707106 in Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control With Metformin Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "S-707106 Dose A",
          "type": "DRUG"
        },
        {
          "name": "S-707106 Dose B",
          "type": "DRUG"
        },
        {
          "name": "S-707106 Dose C",
          "type": "DRUG"
        },
        {
          "name": "Placebo A tablet",
          "type": "DRUG"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shionogi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 218,
      "start_date": "2010-10",
      "completion_date": "2012-01",
      "has_results": false,
      "last_update_posted_date": "2018-05-15",
      "last_synced_at": "2026-10-06T01:53:28.686Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01240759"
    },
    {
      "nct_id": "NCT01125189",
      "title": "Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C Virus"
      ],
      "interventions": [
        {
          "name": "Daclatasvir",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "peg-interferon alfa-2a",
          "type": "DRUG"
        },
        {
          "name": "ribavirin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 558,
      "start_date": "2010-07",
      "completion_date": "2012-08",
      "has_results": true,
      "last_update_posted_date": "2015-10-23",
      "last_synced_at": "2026-10-06T01:53:28.686Z",
      "location_count": 33,
      "location_summary": "Montgomery, Alabama • La Jolla, California • Los Angeles, California + 26 more",
      "locations": [
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01125189"
    },
    {
      "nct_id": "NCT01597401",
      "title": "A Single Dose Study of the Safety, Blood Levels and Biological Effects of Aes-103 Compared to Placebo in Subjects With Stable Sickle Cell Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Sickle Cell Disease"
      ],
      "interventions": [
        {
          "name": "Aes-103",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baxalta now part of Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 19,
      "start_date": "2012-05-12",
      "completion_date": "2013-06-07",
      "has_results": false,
      "last_update_posted_date": "2021-05-05",
      "last_synced_at": "2026-10-06T01:53:28.686Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01597401"
    },
    {
      "nct_id": "NCT01900600",
      "title": "Interleukin-1 Blockade With Canakinumab to Improve Exercise Capacity in Patients With Chronic Systolic Heart Failure and Elevated High Sensitivity C-reactive Protein (Hs-CRP)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Prior Acute Myocardial Infarction",
        "Evidence of Systemic Inflammation (C Reactive Protein Plasma >2 mg/l)",
        "Reduced Left Ventricle Ejection Fraction (<50%)",
        "Symptoms of Heart Failure (NYHA Class II-III)"
      ],
      "interventions": [
        {
          "name": "Cardiopulmonary exercise test",
          "type": "OTHER"
        },
        {
          "name": "Echocardiogram",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Virginia Commonwealth University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "110 Years",
        "sex": "ALL",
        "summary": "18 Years to 110 Years"
      },
      "enrollment_count": 15,
      "start_date": "2013-04",
      "completion_date": "2015-01-08",
      "has_results": false,
      "last_update_posted_date": "2018-10-10",
      "last_synced_at": "2026-10-06T01:53:28.686Z",
      "location_count": 1,
      "location_summary": "Richmond, Virginia",
      "locations": [
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01900600"
    },
    {
      "nct_id": "NCT00637923",
      "title": "Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Hepatitis C Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Hepatitis C"
      ],
      "interventions": [
        {
          "name": "Nitazoxanide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Peginterferon alfa-2a",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ribavirin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Romark Laboratories L.C.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 112,
      "start_date": "2008-03",
      "completion_date": "2010-04",
      "has_results": true,
      "last_update_posted_date": "2014-02-10",
      "last_synced_at": "2026-10-06T01:53:28.686Z",
      "location_count": 10,
      "location_summary": "Palo Alto, California • New Haven, Connecticut • Bay Pines, Florida + 6 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Bay Pines",
          "state": "Florida"
        },
        {
          "city": "Largo",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00637923"
    },
    {
      "nct_id": "NCT04276259",
      "title": "Rapid Antidepressant Improvement Secondary to Excitatory Brain Responses",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Major Depressive Disorder",
        "Depression"
      ],
      "interventions": [
        {
          "name": "Buprenorphine",
          "type": "DRUG"
        },
        {
          "name": "Naltrexone",
          "type": "DRUG"
        },
        {
          "name": "Oral Placebo",
          "type": "DRUG"
        },
        {
          "name": "IM Placebo",
          "type": "DRUG"
        },
        {
          "name": "Theta burst stimulation (TBS) of the ventromedial prefrontal cortex.",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Marta Peciña, MD PhD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 120,
      "start_date": "2020-10-19",
      "completion_date": "2026-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-31",
      "last_synced_at": "2026-10-06T01:53:28.686Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04276259"
    },
    {
      "nct_id": "NCT01054573",
      "title": "VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir Placebo",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hepatitis C, Chronic"
      ],
      "interventions": [
        {
          "name": "Telaprevir",
          "type": "DRUG"
        },
        {
          "name": "pegylated interferon (Peg-IFN) alfa-2a",
          "type": "DRUG"
        },
        {
          "name": "ribavirin (RBV)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Infectious Diseases BVBA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 90,
      "start_date": "2010-04",
      "completion_date": "2012-05",
      "has_results": true,
      "last_update_posted_date": "2013-05-08",
      "last_synced_at": "2026-10-06T01:53:28.686Z",
      "location_count": 14,
      "location_summary": "Coronado, California • Los Angeles, California • San Francisco, California + 11 more",
      "locations": [
        {
          "city": "Coronado",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Bradenton",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01054573"
    }
  ]
}